Advertisement
Singapore markets close in 3 hours 26 minutes
  • Straits Times Index

    3,323.13
    -3.15 (-0.09%)
     
  • Nikkei

    39,700.58
    +527.43 (+1.35%)
     
  • Hang Seng

    18,106.01
    +33.11 (+0.18%)
     
  • FTSE 100

    8,247.79
    -33.76 (-0.41%)
     
  • Bitcoin USD

    61,616.71
    +344.40 (+0.56%)
     
  • CMC Crypto 200

    1,280.88
    +31.75 (+2.54%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • Dow

    39,112.16
    -299.05 (-0.76%)
     
  • Nasdaq

    17,717.65
    +220.84 (+1.26%)
     
  • Gold

    2,327.90
    -2.90 (-0.12%)
     
  • Crude Oil

    81.27
    +0.44 (+0.54%)
     
  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     
  • FTSE Bursa Malaysia

    1,589.82
    +4.44 (+0.28%)
     
  • Jakarta Composite Index

    6,925.67
    +42.96 (+0.62%)
     
  • PSE Index

    6,290.06
    -8.99 (-0.14%)
     

Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

LEXINGTON, Mass., May 23, 2024--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10th – 13th in Miami Beach, Florida. The fireside chat will take place at 8:00 a.m. ET on June 12th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations/.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523361904/en/

Contacts

Investor
917-362-1370
investor@agenusbio.com

Media
612-839-6748
communications@agenusbio.com